Skip to content
Company Analysis

Sonoma Pharmaceuticals, Inc. SNOA

A comprehensive view of key metrics, scores, and financial health for Sonoma Pharmaceuticals, Inc.

Overview of Sonoma Pharmaceuticals, Inc.

SNOA NCM
Healthcare Drug Manufacturers - Specialty & Generic Micro Cap
Sonoma Pharmaceuticals, Inc. (SNOA), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $2.46, about 408.5% undervalued vs fair value, -36.3% 1Y return, ranked 971/1110 in sector.
$2.46
0.41%
As of March 13, 2026
Previous close • Vol 90d: 49.4%
52-Week Range
Market Cap
$4.10M
Enterprise Value
$2.19M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Sonoma Pharmaceuticals, Inc..

Top Beats
No strong beats yet

Quick Facts

Website https://sonomapharma.com
HQ Boulder, CO
Employees 8
Fiscal year Mar 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$11
$13
$14
Current: $2.46 +409% vs base

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$14.3M
12.2%%
Gross Profit
$5.5M
15.2%%
R&D Expense
$1.8M
-3%%
Operating Income (EBIT)
$-3.7M
21.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
12.7%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$1.0K

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Sonoma Pharmaceuticals, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
39
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
45
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing SNOA's balance between Growth (43.3%), Profitability (23.3%), and Safety (33.4%). Growth 43% Safety 33% Profitability 23%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

58th percentile vs peers
59
Key Signals
Rev Growth YoY 12.2% 62p EPS Growth YoY 73.8% 71p Revenue CAGR 3Y 4.2% 44p
Strengths
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

31th percentile vs peers
32
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

45th percentile vs peers
45
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Sonoma Pharmaceuticals, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$12.51
- - -
+408.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info